Paramyotonia congenitaParamyotonia Congenita
📋 Contents and key points
1. History
Paramyotonia Congenita (PMC) was first described in 1886 by the German neurologist Albert von Eulenburg and is also called 'Eulenburg disease' after him. Eulenburg observed a family in which muscle stiffness and paralysis triggered by exercise and exposure to cold appeared across several generations, and documented it systematically. The term 'paramyotonia' was adopted to emphasize the paradoxical feature that, although similar to myotonia congenita (Thomsen disease), it worsens with exercise (no warm-up). Until the mid-20th century, classification was based on clinical phenotype, but in 1991 Ptácek et al. first identified gain-of-function variants in the SCN4A gene (the gene encoding the sodium ion channel Nav1.4) as the cause of PMC. Subsequently, as phenotypic spectrum continuity was revealed between SCN4A variants and hyperkalemic periodic paralysis (HypoPP type 2) and various sodium channel-related phenotypes, an integrated understanding of SCN4A-related ion channelopathies developed. Today, PMC is classified as the representative phenotype among SCN4A-related sodium channelopathies characterized by cold-induced myotonia and paralysis.
2. Causes
Paramyotonia congenita is an autosomal dominant disorder caused by gain-of-function pathogenic variants in the SCN4A gene (17q23.3). SCN4A encodes the alpha subunit of the skeletal muscle voltage-gated sodium channel (Nav1.4), which is essential for the initiation and propagation of muscle action potentials.
- SCN4A variants associated with PMC are mainly missense variants that delay or impair inactivation of the Nav1.4 channel, producing a persistent sodium current.
- Representative variants: p.R1448C, p.R1448H, p.T1313M, p.L1433R, etc. These are mainly located in the S4 or S4-S5 linker region of domain 4 (DIV) of the channel.
- In addition to PMC, SCN4A variants are associated with various phenotypes such as hyperkalemic periodic paralysis (HyperPP), a myotonia congenita-like form, and hypokalemic periodic paralysis type 2 (HypoPP type 2). Some variants present a combined phenotype (PMC + periodic paralysis).
3. Genetics
PMC follows an autosomal dominant inheritance pattern and is transmitted from an affected parent to a child with a 50% probability. De novo mutations also occur rarely. Penetrance is generally high, but expressivity varies by variant. Diagnosis is confirmed by sequencing of the entire SCN4A gene or a gene panel. A genotype-phenotype correlation exists to some degree, but variation in symptom severity is observed even within families carrying the same variant.
| Phenotypes associated with SCN4A variants | Features |
| Paramyotonia congenita (PMC) | Cold- and exercise-induced myotonia → progresses to paralysis, no warm-up |
| Hyperkalemic periodic paralysis (HyperPP) | Episodic paralysis, elevated serum potassium, may be accompanied by myotonia |
| Sodium channel myotonia (SCM) | Predominantly myotonia, no paralysis |
| Hypokalemic periodic paralysis type 2 (HypoPP2) | Episodic paralysis, decreased serum potassium |
4. General epidemiology
Paramyotonia congenita is a very rare disease, and its exact prevalence is difficult to estimate. Worldwide prevalence is estimated at about 1/200,000–1/500,000, but the actual prevalence may be higher due to underdiagnosis. Prevalence is equal between sexes, and it is known to occur in all ethnic groups. In some European countries, specific founder mutations are observed at relatively high frequency within populations. Diagnosis is commonly delayed in patients with mild clinical symptoms, so the actual number of patients is likely greater than reported. Age of onset varies from birth to childhood, and symptom onset may be related to region and season, reflecting sensitivity to cold.
5. Pathophysiology
The Nav1.4 channel is responsible for the depolarization phase of the skeletal muscle action potential, and normally fast inactivation occurs within a few milliseconds after the action potential, restoring the membrane potential to its resting state. SCN4A gain-of-function variants associated with PMC impair or delay this inactivation process, causing the channel to remain in the open state abnormally long or to repeatedly reactivate.
As a result, a persistent inward sodium current occurs, placing the muscle cell membrane in a state of excessive depolarization. Initially, myotonia appears due to repetitive action potentials; if excessive depolarization persists, most sodium channels become locked in the inactivated state and depolarization block occurs, in which action potentials can no longer be generated, and this manifests as clinical paralysis.
Symptom worsening with cold occurs because inactivation of the Nav1.4 channel is further delayed at low temperatures, increasing the persistent sodium current. This explains why PMC, unlike myotonia congenita (ClC-1 variants), lacks the warm-up phenomenon and instead worsens with continued exercise.
6. Symptoms
Key clinical features
- Cold-induced myotonia: Myotonia occurs upon exposure to cold environments (cold air, contact with cold water). Prominent in the muscles of the face (eyelids, perioral area), hands, and arms.
- Exercise-induced myotonia and paradoxical worsening: A paradoxical phenomenon in which myotonia worsens after sustained exercise (paradoxical myotonia). The warm-up phenomenon is absent or incomplete — the key distinguishing point from myotonia congenita (Thomsen/Becker).
- Progression to paralysis after exercise: If cold or exercise continues after the initial myotonia, muscle weakness and paralysis develop. Paralysis lasts from minutes to hours and then resolves spontaneously. Resolution of paralysis is faster when body temperature rises.
Affected areas
- Facial muscles: eyelid stiffness, stiffness of the muscles of facial expression.
- Upper limbs: stiffness and paralysis of the hand and forearm muscles.
- Lower limbs: in severe cases, inability to walk due to lower limb paralysis.
- Oropharynx: dysarthria, dysphagia (rarely).
Accompanying periodic paralysis
- Some PMC patients show a phenotype overlapping with hyperkalemic periodic paralysis (HyperPP), and episodic paralysis may occur due to food (high-potassium foods), rest after exercise, fasting, etc.
7. Signs
Clinical examination
- Cold-induced myotonia provocation test: Immersing the hand in ice water or applying cold water to the muscle provokes myotonia within minutes. The course of progression to paralysis with continued exposure is then observed.
- Percussion myotonia: Percussion of the thenar muscle or tongue provokes myotonic discharge. Becomes more pronounced after cold exposure.
- Paradoxical myotonia: A finding in which relaxation becomes more difficult as repetitive hand-grip movements are continued.
EMG findings
- At room temperature, myotonic discharges may be mild or absent.
- When the muscle is cooled, myotonic discharges increase markedly, followed by a decrease in CMAP amplitude (reflecting the paralysis phase).
- Long exercise test: a progressive decrease in CMAP after exercise is characteristic.
Laboratory findings
- Serum CK: normal or mildly elevated.
- Serum potassium during paralytic attacks: normal or elevated (when overlapping with the hyperkalemic form).
- Electrocardiogram: normal (no cardiac involvement from PMC itself).
8. Screening
- History taking: Check for cold- or exercise-induced muscle stiffness, whether it progresses to paralysis, paradoxical myotonia (worsening with continued exercise), and family history.
- Serum CK: For screening purposes (a normal result cannot exclude the disease).
- Electrocardiogram: Check for abnormalities related to hypokalemia or hyperkalemia in patients with accompanying periodic paralysis.
- EMG (including cooling protocol): Check EMG changes before and after muscle cooling — increased myotonic discharges and decreased CMAP after cooling are important for diagnosis.
- Long exercise test: Check for a pattern of progressive CMAP decrease after maximal exercise.
9. Diagnosis
The diagnosis is suspected based on clinical features (cold- and exercise-induced paradoxical myotonia, progression to paralysis) and EMG findings, and confirmed by molecular genetic testing of the SCN4A gene.
Molecular genetic testing
- SCN4A gene sequencing (Sanger sequencing or NGS). Identification of known pathogenic variants and evaluation of novel variants.
- Gene panel: simultaneous analysis of channelopathy genes such as SCN4A, CLCN1, CACNA1S, and KCNJ2.
Ancillary diagnosis
- EMG (cooling protocol, long exercise test): essential electrophysiological evaluation.
- Cold provocation test (ice-water immersion test): observe provocation of myotonia and paralysis after immersing the hand in 15°C cold water.
Differential diagnosis
- Myotonia congenita (CLCN1 variants): warm-up phenomenon, no paralysis, no CMAP decrease with cooling.
- Hyperkalemic periodic paralysis (HyperPP): no or mild myotonia, elevated serum potassium.
- Hypokalemic periodic paralysis (HypoPP): decreased serum potassium, no myotonia.
- Myotonic dystrophy (DM1): multiorgan involvement, warm-up phenomenon, repeat expansion gene mutation.
10. Treatment
Patients with mild symptoms can be managed by avoiding cold and excessive exercise alone. If symptoms impair daily functioning, drug treatment is considered.
Drug therapy
- Mexiletine: Reduces the frequency of myotonia and paralysis through sodium channel blockade. Adult dose 150–200 mg 2–3 times daily. Regarded as the most effective drug in PMC. Use with caution in patients with cardiac conduction abnormalities.
- Acetazolamide: A carbonic anhydrase inhibitor. Used to prevent attacks in patients with accompanying periodic paralysis. Some efficacy has also been reported in PMC alone. Watch for adverse effects of nephrolithiasis and metabolic acidosis.
- Carbamazepine: Used in some patients via a sodium channel-blocking mechanism.
- Flecainide: Efficacy reported in some studies as an alternative to mexiletine.
Non-pharmacological treatment
- Avoiding cold exposure: appropriate cold-weather clothing, minimizing direct contact with cold water.
- Adjusting exercise intensity: avoiding sustained high-intensity exercise.
- Restricting high-potassium foods: managing potassium triggers in patients with accompanying periodic paralysis.
- Maintaining body temperature: when paralysis occurs, promote recovery from paralysis by rapidly raising body temperature (moving to a warm environment, applying heating pads).
Anesthetic management
- Use depolarizing muscle relaxants (succinylcholine) with caution.
- Maintaining body temperature during surgery is essential — hypothermia can trigger a myotonic crisis.
- Inform the anesthesiology department of the diagnosis before anesthesia and discuss a special protocol.
11. Prognosis
Paramyotonia congenita rarely causes life-threatening complications and has a nonprogressive course. Most patients have a normal life expectancy. Symptoms can be effectively controlled by avoiding cold and with drug treatment. In some patients, the frequency or severity of paralytic attacks may change with increasing age, and some may develop persistent mild muscle weakness. When periodic paralysis is present, there are reports that repeated paralytic attacks can lead to permanent muscle weakness in the long term, so early treatment and management of triggers are important. Symptoms may change during pregnancy, and the effect on the newborn is minimal.
12. Prevention
- Genetic counseling: Explain the autosomal dominant inheritance pattern. 50% risk of disease in children of an affected parent. Provide family genetic counseling after molecular confirmation.
- Preimplantation genetic testing (PGT-M): Pre-reproductive screening is available if desired.
- Avoiding triggers: Avoid cold exposure and sustained overload exercise. Take appropriate cold protection measures, especially during cold-water swimming and outdoor low-temperature activities.
- Establishing an emergency plan: Educate on how to respond to severe paralytic attacks (moving to a warm environment, oral glucose intake, visiting the emergency room if necessary).
- Choice of occupation and activities: Refrain from occupations with frequent exposure to low-temperature environments (such as working in cold storage warehouses).
- Advance notice for surgery and anesthesia: Share the diagnosis and precautions with anesthesiology and surgery in advance.
13. References
- Ptácek LJ, George AL Jr, Griggs RC, et al. Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell. 1991;67(5):1021–1027. PMID: 1659948
- Lerche H, Heine R, Pika U, et al. Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III-IV linker. J Physiol. 1993;470:13–22. PMID: 8308735
- Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018;57(4):522–530. PMID: 28846808
- Heine R, Pika U, Lehmann-Horn F. A novel SCN4A mutation causing myotonia aggravated by cold and potassium. Hum Mol Genet. 1993;2(9):1349–1353. PMID: 8242056
- Suetterlin KJ, Männikkö R, Hanna MG. Mutation-specific effects of mexiletine on sodium channel function in a mouse model of myotonia. Exp Neurol. 2015;270:28–37. PMID: 25930180
- Vicart S, Sternberg D, Fontaine B, Meola G. Human skeletal muscle sodium channelopathies. Neurol Sci. 2005;26(4):194–202. PMID: 16193245
- Weber MA, Nielles-Vallespin S, Huttner HB, et al. Evaluation of patients with paramyotonia at 31P MRS. Neurology. 2006;66(10):1621–1627. PMID: 16769952
- Kim JB. Channelopathies. Korean J Pediatr. 2014;57(1):1–18. PMID: 24578715
- Stunnenberg BC, Raaphorst J, Groenewoud HM, et al. Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials. JAMA. 2018;320(22):2344–2353. PMID: 30535218
- Riggs JE, Griggs RC. Diagnosis and treatment of the periodic and myotonic paralysis syndromes. Neurol Clin. 1983;1(1):51–64. PMID: 6634580